MICRO-K LS Drug Patent Profile

When do Micro-k Ls patents expire, and what generic alternatives are available?

Micro-k Ls is a drug marketed by Kv Pharm and is included in one NDA.

The generic ingredient in MICRO-K LS is potassium chloride. There are two hundred and forty drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Micro-k Ls

A generic version of MICRO-K LS was approved as potassium chloride by ACTAVIS LABS FL INC on April 10^th, 2002.

Summary for MICRO-K LS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	314
DailyMed Link:	MICRO-K LS at DailyMed

US Patents and Regulatory Information for MICRO-K LS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kv Pharm	MICRO-K LS	potassium chloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	019561-003	Aug 26, 1988		DISCN	Yes	No

Expired US Patents for MICRO-K LS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kv Pharm	MICRO-K LS	potassium chloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	019561-003	Aug 26, 1988	4,259,315

International Patents for MICRO-K LS

See the table below for patents covering MICRO-K LS around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	61817	PHARMACEUTICAL COMPOSITIONS COMPRISING CONTROLLED RELEASE POTASSIUM SALT FORM
Netherlands	8100468
Italy	8167071
Netherlands	192430
Japan	S5714525	SLOW-RELEASE POTASSIUM AGENT
Switzerland	648206	COMPOSITIONS PHARMACEUTIQUES A LIBERATION CONTROLEE DE POTASSIUM.

Supplementary Protection Certificates for MICRO-K LS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1718641	2012/008	Ireland		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1499331	SPC/GB13/034	United Kingdom		PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215

Market Dynamics and Financial Trajectory for MICRO-K LS

Last updated: February 20, 2026

What is MICRO-K LS and its current market status?

MICRO-K LS is a prescription drug primarily used for electrolyte replenishment and management of potassium deficiencies. It contains a combination of potassium chloride, sodium chloride, and other electrolytes. The drug is marketed by major pharmaceutical companies and has received regulatory approval in several jurisdictions, including the U.S., Europe, and Asia.

The global electrolyte replacement therapy market, where MICRO-K LS is positioned, was valued at approximately USD 2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2022 to 2028, driven by rising prevalence of chronic kidney disease, gastrointestinal disorders, and increased awareness of electrolyte balance importance.

What are the key market drivers?

The primary factors influencing MICRO-K LS's market include:

• Aging Population: Older adults, especially in North America and Europe, experience higher rates of electrolyte imbalances due to comorbidities and medication use.

• Chronic Diseases: Rising incidences of chronic kidney disease and heart failure increase demand for electrolyte therapies.

• Hospitalizations and Critical Care: Increased global hospitalization rates for COVID-19 and other illnesses necessitate electrolyte management.

• Product Adoption: Adoption of MICRO-K LS versus alternative therapies depends on efficacy, safety, and ease of administration. The formulation's tolerability and dosing flexibility impact market penetration.

• Regulatory Environment: Accelerated approval pathways and expanded indications can influence market size. Regulatory delays or restrictions can limit growth.

What are the competitive and market challenges?

• High Competition: The market features multiple formulations, including other potassium chloride and electrolyte products. Generic versions pressure pricing and margins.

• Pricing Pressures: Payers and insurance providers seek cost-effective therapies. Reimbursement policies influence sales trajectories.

• Market Penetration: Physicians' prescribing habits depend on perceived safety and convenience. Differentiating features of MICRO-K LS must be clear.

• Supply Chain Disruptions: Production challenges, raw material shortages, and logistic issues can impact availability.

What are the recent financial trends?

Financial data specific to MICRO-K LS is limited publicly. However, considering the broader electrolyte therapy segment, key insights include:

• Sales Growth: Companies reporting increased electrolyte therapy revenues noted a CAGR of 4-6% over the past three years, attributed to pandemic-driven hospital sector demand.

• Profit Margins: Gross margins for electrolyte products range from 30% to 45%. Premium formulations or those with unique delivery systems may command higher margins.

• R&D Investment: Major players invest 8-12% of their revenue into R&D annually. For MICRO-K LS competitors, innovation focuses on formulations with fewer adverse effects and improved bioavailability.

• Market Share Dynamics: Established pharma firms, such as Fresenius Kabi and Baxter, dominate the electrolyte market, holding over 60% combined market share.

How is the regulatory landscape influencing future prospects?

Regulatory agencies, including the FDA and EMA, emphasize post-marketing surveillance and safety data for electrolyte therapies. Recent focus areas involve:

• Labeling for New Indications: Expanded use in specific patient populations can grow the market.

• Manufacturing Standards: Strict Good Manufacturing Practice (GMP) enforcement influences production costs.

• Pricing and Reimbursement: Payers' policies impact sales; innovative billing codes and coverage decisions can accelerate or hinder adoption.

What are the future projections?

Based on the current trends:

Parameter	Projection (2022-2028)
Market CAGR	5.8%
Total Market Size	USD 3.4 billion (by 2028)
MICRO-K LS Market Share	Expected to hold or increase, depending on approval of new indications and formulations
R&D Spending	Continued 8-12% of revenue
Innovation Focus	Oral formulations with fewer side effects

Key Takeaways

• MICRO-K LS operates within a steadily growing electrolyte therapy market driven by demographic and health trends.
• Market competition is intense with pricing pressure from generics and payers.
• Future growth relies on regulatory approvals, product differentiation, and increased clinical use.
• Financial performance is tied to hospital sector demand, reimbursement policies, and R&D investment.

FAQs

1. What factors could limit the growth of MICRO-K LS?
Supply chain disruptions, pricing pressures from payers, and competition from generic formulations could constrain sales growth.

2. How does regulatory approval impact the market?
Approval for new indications or formulations enhances market size, while delays or restrictions can hinder growth.

3. What distinguishes MICRO-K LS from competitors?
Formulation tolerability, dosing flexibility, and safety profile are key differentiators influencing physician preference.

4. How does reimbursement policy influence sales?
Positive coverage and reimbursement policies increase prescribing, while restrictive policies reduce access and sales.

5. What is the outlook for innovation in electrolyte therapies?
Focus remains on oral formulations with improved safety and efficacy, which could capture larger market share.

---

References

[1] IMARC Group. (2022). Electrolyte Replacement Therapy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028.
[2] Deloitte. (2021). Global Healthcare Outlook.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.